Page last updated: 2024-12-04

nicotine imine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nicotine imine: RN given refers to 11C-labeled (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID431
CHEBI ID173425
MeSH IDM0106619

Synonyms (9)

Synonym
CHEBI:173425
3-(1-methyl-3,4-dihydro-2h-pyrrol-1-ium-2-yl)pyridine
nicotine imine
nicotine-delta 1'-(5')-iminium
(s)-1-(methylene-11c)-2-(3-pyridinyl)-pyrrolidium
Q47459681
3,4-dihydro-1-methyl-2-(3-pyridinyl)-2h-pyrrolium
DTXSID801231086
72344-33-3

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An alternate metabolic route entails hydrolysis of nicotine iminium to an open-chain ketoamine that, in turn, undergoes nitrosation to form a toxic nitrosamine."( Iminium metabolite mechanism for nicotine toxicity and addiction: Oxidative stress and electron transfer.
Cooksy, A; Kovacic, P, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
citraconoyl group
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Nicotine Action Pathway3832
Nicotine Metabolism Pathway923
Nicotine metabolism011
Nicotine metabolism in liver cells011

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's2 (28.57)18.2507
2000's2 (28.57)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]